Page last updated: 2024-08-22

camptothecin and Prostatic Neoplasms

camptothecin has been researched along with Prostatic Neoplasms in 103 studies

Research

Studies (103)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	15 (14.56)	18.2507
2000's	46 (44.66)	29.6817
2010's	40 (38.83)	24.3611
2020's	2 (1.94)	2.80

Authors

Authors	Studies
Chai, HB; Fan, Z; Fong, HH; Pezzuto, JM; Sun, H; Tan, GT; Zhang, H	1
Henne, WA; Kularatne, SA; Low, PS; Santhapuram, HK; Vaitilingam, B; Venkatesh, C; Wang, K	1
Bandey, AH; Chashoo, G; Mondhe, D; Qazi, GN; Qazi, NA; Reddy, DM; Sampath Kumar, HM; Sawant, SD; Saxena, A; Saxena, AK; Sethi, VK; Shankar, M; Singh, SK; Srinivas, J; Taneja, SC; Verma, M	1
Ahmed Ali, AA; Chang, DM; Chang, WW; Chen, CL; Chen, TC; Guh, JH; Huang, HS; Lee, CC; Liu, FL	1
Alajati, A; Alimonti, A; Aversa, C; Bertan, C; Bianchini, D; Boysen, G; Brina, D; Buroni, L; Califano, A; Carreira, S; Christova, R; Clarke, M; Crespo, M; D'Ambrosio, M; de Bono, J; Dolling, D; Ferreira, A; Figueiredo, I; Flohr, P; Fowler, G; Gil, V; Guo, C; Gurel, B; Lambros, M; Miranda, S; Neeb, A; Ning, J; Paschalis, A; Pereira, R; Rekowski, J; Rescigno, P; Riisnaes, R; Seed, G; Sharp, A; Sheehan, B; Shen, MM; Sumanasuriya, S; Swain, A; Troiani, M; Tunariu, N; Vasciaveo, A; Welti, J; Workman, P; Yuan, W	1
Campbell, SJ; Dufès, C; Irving, C; Keating, P; Laskar, P; Leung, HY; Mullin, M; Somani, S; Tate, RJ	1
Freeman, MR; Hemler, ME; Sharma, C; Steen, H; Yang, W	1
Doi, H; Inui, T; Kataoka, Y; Kida, T; Nakatsuji, M; Nishino, K; Sakamoto, S; Shimizu, S; Tamura, Y; Teraoka, Y	1
Cai, JJ; Imperato-McGinley, J; Tan, C; Wang, G; Wang, LP; Wang, X; Zhu, YS	1
Li, S; Ran, X; Wang, J; Zhang, G	1
Antonioli, E; Belizário, JE; Caldeira, I; Carreira, ACO; de Assis Santos, I; Garay-Malpartida, HM; Goldberg, AC; Maciel-Silva, P; Siqueira, FR	1
Afkham, A; Afkham, NM; Aghebati-Maleki, L; Ahmadi, M; Akbarzadeh, P; Dolati, S; Jadidi-Niaragh, F; Sadreddini, S; Siahmansouri, H; Younesi, V; Yousefi, M	1
Fang, X; Fu, T; He, N; Huang, Q; Peng, Y; Sun, W; Tan, W; Wang, P; Zhang, P; Zhao, Z; Zhou, F	1
Abe, T; Fukaya, M; Itatsu, K; Nagino, M; Yokoyama, Y	1
Bowen, C; Gelmann, EP; Song, LN	1
Chatterjee, D; Cross-Knorr, S; Del Tatto, M; Dillard, C; Goldstein, L; Mills, D; Panagopoulos, K; Pantazatos, D; Quesenberry, P; Renzulli, J	1
Erbaykent-Tepedelen, B; Gonen-Korkmaz, C; Karamil, S; Korkmaz, KS	1
Chen, Z; Feng, Y; Guo, R; He, M; Hong, Z; Kong, X; Li, M; Li, Y; Tian, R; Wang, J; Wu, W; Yu, K; Yu, M	1
Chang, PL; Chen, WT; Chiang, KC; Chung, LC; Juang, HH; Tsui, KH; Yeh, CN	1
Aoyama, T; Hamano, T; Hashimura, T; Kawai, J; Kimura, H; Uegaki, M	1
McGregor, N; Pienta, KJ; Wang, X; Wu, M; Zhang, J	1
Fox, JL; Storey, A	1
Chang, WY; Choi, YH; Hyun, JW; Jayasooriya, RG; Kim, GY; Park, SR	1
Barrera, G; Boggio, E; Cappellano, G; Cavalli, R; Conti, L; Dianzani, C; Dianzani, U; Fantozzi, R; Gigliotti, CL; Giovarelli, M; Minelli, R; Occhipinti, S; Pizzimenti, S; Trotta, F	1
Chen, SH; Chern, CS; Chiang, WH; Chiu, HC; Huang, CW; Huang, WC; Lo, CL	1
Akao, Y; Deguchi, T; Fujita, Y; Hamada, N; Ito, M; Kojima, K; Nozawa, Y; Ohhashi, R	2
Cuvillier, O; Doumerc, N; Golzio, M; Kohama, T; Malavaud, B; Naymark, M; Pchejetski, D; Teissié, J; Waxman, J	1
Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W	1
Izumi, K; Mouri, H; Ohtsubo, K; Watanabe, H; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K; Zen, Y	1
Liu, S; Okumura, Y; Shinkai, N; Yamauchi, H; Yuan, Y	1
Farach-Carson, MC; Gurski, LA; Jia, X; Pochan, DJ; Wang, X; Xu, X; Zhong, S	1
Chang, PL; Feng, TH; Juang, HH; Lin, YF; Tsui, KH	1
Aigner, A; Czubayko, F; Frömberg, A; Gutsch, D; Schulze, D; Vollbracht, C; Weiss, G	1
Gleave, M; Gout, PW; Liu, DM; Tung, WL; Wang, Y	1
Cui, J; Li, C; Li, Y; Wang, C; Wang, P; Wei, N; Xiu, X; Zhang, L	1
Ando, M; Deguchi, T; Ito, M; Itoh, T; Kojima, K; Nakane, K; Nozawa, Y; Terazawa, R; Tsukamasa, Y	1
Debelec-Butuner, B; Erbaykent-Tepedelen, B; Gonen-Korkmaz, C; Korkmaz, KS; Muhammed Syed, H; Ozmen, B; Varisli, L; Yilmazer-Cakmak, O	1
Kozłowska, E; Orzechowska, E; Staroń, K; Trzcińska-Danielewicz, J	1
Fadlalla, K; Katkoori, V; Manne, U; Mosley, L; Samuel, T; Turner, T	1
Chen, CS; Guh, JH; Ho, YF; Hsu, JL; Hsu, LC; Li, TK	1
Barrera, G; Cavalli, R; Ciamporcero, E; Dianzani, C; Ellis, L; Fantozzi, R; Minelli, R; Pettazzoni, P; Pili, R; Trotta, F	1
Alloatti, D; Badaloni, E; Cabri, W; Castorina, M; Giannini, G; Pisano, C; Vesci, L	1
Bander, NH; Farokhzad, OC; Gadde, S; Kantoff, PW; Karnik, R; Langer, R; Lippard, SJ; Perea, B; Pridgen, EM; Sweeney, C; Valencia, PM	1
Choi, KC; Hwang, KA; Kim, SU; Kim, YB; Yi, BR	1
Babcook, MA; Bhaskaran, N; Gupta, K; Gupta, S; Jackson, MW; Nawab, A; Thakur, VS	1
Commes, T; Hammers, H; Kachhap, SK; Kaelber, NS; Kant, H; Kim, E; Liu, JO; Mendonca, J; Shim, JS; Van Diest, PJ; Wissing, MD	1
Agrawal, S; Wang, H; Yu, D; Zhang, R	1
Caiolfa, VR; Castelli, MG; D'Argy, R; Farao, M; Fiorino, A; Fontana, E; Ghiglieri, A; Gratton, E; Pesenti, E; Suarato, A; VandeVen, M; Zamai, M	1
Alexander, J; Kirsch, IR; Kohn, KW; Kouros-Mehr, H; Lababidi, S; Liu, E; Maunakea, AK; Miller, L; Pantazis, P; Pommier, Y; Reinhold, WC; Roschke, A; Stover, K; Urasaki, Y; Weinstein, JN	1
Cho, YS; Cho-Chung, YS	1
Bucci, F; Carenini, N; Carminati, P; De Cesare, M; Gatti, L; Martinelli, R; Perego, P; Pisano, C; Pratesi, G; Supino, R; Zanier, R; Zuco, V; Zunino, F	1
Adams, DJ; Colvin, OM; Dewhirst, M; Driscoll, TA; Flowers, JL; Friedman, HS; Hoffman, RM; Manikumar, G; Wall, ME; Wani, MC	1
Almasan, A; Ray, S	1
Bailly, C; Colson, P; Facompré, M; Goossens, JF; Hénichart, JP; Houssier, C; Houssin, R; Marty, C; Perzyna, A; Pommery, N	1
Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL	1
Conticello, C; De Maria, R; Messina, A; Patti, M; Pedini, F; Peschle, C; Stassi, G; Zerilli, M; Zeuner, A	1
Braastad, CD; Chatterjee, D; Darnowski, J; Goldman, M; Goodglick, L; Pantazis, P; Wyche, JH	1
Bigg, DC; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, PG; Lavergne, O; Lesueur-Ginot, L; Prévost, G	1
Ganapathi, R; Malathi, K; Paranjape, JM; Silverman, RH	1
Paukstadt, W	1
Hu, H; Ip, C; Jiang, C; Lü, J; Rustum, YM	1
Hoffman, RM	1
Bonhoure, E; Calvet, C; Cuvillier, O; Doumerc, N; Garcia, V; Golzio, M; Malavaud, B; Mazerolles, C; Pchejetski, D; Rischmann, P; Teissié, J	1
Carenini, N; Ciusani, E; Corna, E; Gatti, L; Perego, P; Zunino, F	1
Duncan, J; McLeod, HL; Scheffer, GL; Scheper, RJ; Shannon, WD; Zhang, W	1
Akao, Y; Banno, Y; Hasegawa, N; Igarashi, Y; Kim, TJ; Murate, T; Nakagawa, Y; Nozawa, Y	1
Coy, DH; Fuselier, JA; Luo, J; Mackey, LV; Sun, LC	1
Cheng, Y; He, Q; He, X; Hu, Y; Lu, W; Luo, P; Yang, B	1
Castilla, C; Chinchón, D; Congregado, B; Japón, MA; Sáez, C; Torrubia, FJ	1
Deguchi, T; Hasegawa, N; Matsumoto, K; Mizutani, K; Nozawa, Y	1
Deguchi, T; Hasegawa, N; Mizutani, K; Nozawa, Y; Suzuki, T	1
Almasan, A; Fraizer, GC; Ray, S; Shyam, S	1
Araki, T; Fujii, M; Inoue, S; Kimoto, K; Murakami, M; Ohshiro, Y; Oka, K; Tacho, T; Yano, A	1
Bjartell, A; Culig, Z; Persson, JL; Wegiel, B	1
Cai, LQ; Chen, GQ; Imperato-McGinley, J; Qiao, Y; Tan, C; Wu, W; Zhu, YS	1
Aulicino, C; Benedetti, V; Bucci, F; Carminati, P; De Cesare, M; Foderà, R; Penco, S; Pisano, C; Vesci, L; Zuco, V; Zunino, F	1
Boothman, DA; Church, DR; Frydman, B; Hutson, P; Planchon, SM; Wilding, G; Witiak, DT; Wuerzberger, S	1
Giaccone, G; Lopez, R; Peters, GJ; Pinedo, HM; Smitskamp-Wilms, E; van Ark-Otte, J; Virizuela, JA	1
Dilworth, A; Myers, CE; Sinha, BK; Yamazaki, H	1
Fox, SC; Giantonio, BJ; Greenberg, R; Hudes, GR; Kosierowski, R; McAleer, CA; Ozols, RF; Ramsey, HE	1
Lehr, JE; Naik, H; Pienta, KJ	1
Chatterjee, D; Pantazis, P; Wyche, JH	1
Roth, BJ	1
Guinan, P; Lievano, G; Mirochnik, Y; Rubenstein, M; Shaw, M	1
Chatterjee, D; DeJesus, A; Early, J; Giovanella, B; Pantazis, P; Plaschke, S; Wyche, J	1
Michael, M; Moore, MJ	1
Cooper, MR; de Souza, PL; Imondi, AR; Myers, CE	1
Ames, MM; Aytes, SA; Kuffel, MJ; Lineswala, JP; Zembower, DE; Zhang, H	1
Smith, DC	1
Costa-Pereira, AP; Cotter, TG	1
Beebe, JR; Bielawska, A; Pwiti, L; Smyth, MJ; Wang, XZ	1
Costa-Pereira, AP; Cotter, TG; McKenna, SL	1
Pommier, Y; Takebayashi, Y; Urasaki, Y	1
Bigg, D; Carlson, M; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, P; Lauer, J; Lavergne, O	1
Bailly, C; Bigg, DC; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, PG; Lavergne, O; Lesueur-Ginot, L	1
Chatterjee, D; Gioffre, C; Kohlhagen, G; Laco, GS; Pantazis, P; Pommier, Y; Pourquier, P; Takebayashi, Y; Urasaki, Y; Zhang, H	1
Boothman, DA; Bornmann, WG; Pink, JJ; Planchon, SM; Tagliarino, C; Varnes, ME	1
Chatterjee, D; Kirchhoff, S; Krammer, PH; Krueger, A; Pantazis, P; Peter, ME; Schmitz, I; Wyche, JH; Yeung, K	1
Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T	1
Akao, Y; Banno, Y; Hattori, M; Hirabayasi, Y; Kito, M; Kusakabe, S; Nakagawa, Y; Nozawa, Y; Ohishi, N; Sawada, M; Tamiya-Koizumi, K	1
Agrawal, S; Ball, R; Chen, SF; Dexter, DL; Hollister, BA; Kandimalla, ER; Lombardi, G; Lucas, T; Yu, D	1
Agrawal, S; Hang, J; Kandimalla, ER; Li, M; Shi, Z; Wang, H; Yu, D; Zhang, R	1

Reviews

3 review(s) available for camptothecin and Prostatic Neoplasms

Article	Year
[Carboplatin plus irinotecan induced partial response in a patient with small cell carcinoma of the prostate; a case report]. Hinyokika kiyo. Acta urologica Japonica, 2014, Volume: 60, Issue:1 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Creutzfeldt-Jakob Syndrome; Fatal Outcome; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Phosphopyruvate Hydratase; Prostate; Prostatic Neoplasms; Transurethral Resection of Prostate; Treatment Outcome	2014
New therapeutic agents for hormone-refractory prostate cancer. Seminars in oncology, 1996, Volume: 23, Issue:6 Suppl 14 Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Estramustine; Humans; Male; Metalloendopeptidases; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Vinblastine; Vinorelbine	1996
Chemotherapy for hormone refractory prostate cancer. The Urologic clinics of North America, 1999, Volume: 26, Issue:2 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cyclophosphamide; Estramustine; Humans; Male; Prostatic Neoplasms; Suramin	1999

Trials

1 trial(s) available for camptothecin and Prostatic Neoplasms

Article	Year
Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Investigational new drugs, 1995, Volume: 13, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostatic Neoplasms; Topotecan; Treatment Outcome	1995

Other Studies

99 other study(ies) available for camptothecin and Prostatic Neoplasms

Article	Year
Pseudoirroratin A, a new cytotoxic ent-kaurene diterpene from Isodon pseudo-irrorata. Journal of natural products, 2002, Volume: 65, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Diterpenes; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Female; Humans; Inhibitory Concentration 50; KB Cells; Lamiaceae; Lung Neoplasms; Male; Molecular Conformation; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Osteosarcoma; Ovarian Neoplasms; Plants, Medicinal; Prostatic Neoplasms; Spectrophotometry, Ultraviolet; Stereoisomerism; Tumor Cells, Cultured	2002
Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs. Journal of medicinal chemistry, 2010, Nov-11, Volume: 53, Issue:21 Topics: Antigens, Surface; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Glutamate Carboxypeptidase II; Glutarates; Humans; Ligands; Male; Molecular Targeted Therapy; Prodrugs; Prostatic Neoplasms; Structure-Activity Relationship; Urea	2010
Design and synthesis of spiro derivatives of parthenin as novel anti-cancer agents. European journal of medicinal chemistry, 2011, Volume: 46, Issue:8 Topics: 4-Butyrolactone; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Ehrlich Tumor; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; DNA Fragmentation; Humans; Male; Mice; Neoplasm Transplantation; NF-kappa B; Nitriles; Oxides; Prostatic Neoplasms; Sesquiterpenes; Spiro Compounds; Structure-Activity Relationship	2011
Ring fusion strategy for the synthesis of anthra[2,3-d]oxazole-2-thione-5,10-dione homologues as DNA topoisomerase inhibitors and as antitumor agents. European journal of medicinal chemistry, 2014, Nov-24, Volume: 87 Topics: Anthraquinones; Antineoplastic Agents; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Male; Molecular Structure; Oxazoles; Prostatic Neoplasms; Structure-Activity Relationship; Topoisomerase Inhibitors; Tumor Cells, Cultured	2014
HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer research, 2021, 12-15, Volume: 81, Issue:24 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Apoptosis; Biomarkers, Tumor; Camptothecin; Cell Proliferation; Follow-Up Studies; Humans; Male; Mice, Inbred NOD; Mice, SCID; Neuregulin-1; Organoids; Prognosis; Prospective Studies; Prostatic Neoplasms; Receptor, ErbB-3; Survival Rate; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays	2021
Camptothecin-based dendrimersomes for gene delivery and redox-responsive drug delivery to cancer cells. Nanoscale, 2019, Nov-14, Volume: 11, Issue:42 Topics: Camptothecin; Dendrimers; Drug Delivery Systems; Drug Resistance, Neoplasm; Gene Transfer Techniques; Humans; Male; PC-3 Cells; Prostatic Neoplasms	2019
Antioxidant functions of DHHC3 suppress anti-cancer drug activities. Cellular and molecular life sciences : CMLS, 2021, Volume: 78, Issue:5 Topics: Acyltransferases; Antineoplastic Agents; Antioxidants; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Gefitinib; Humans; Lapatinib; Male; Prostatic Neoplasms; RNA Interference	2021
Solubility-Improved 10-O-Substituted SN-38 Derivatives with Antitumor Activity. ChemMedChem, 2017, 10-20, Volume: 12, Issue:20 Topics: Animals; Antineoplastic Agents; Camptothecin; Humans; Irinotecan; Male; Mice; Molecular Structure; Neoplasms, Experimental; Prostatic Neoplasms; Structure-Activity Relationship	2017
Dual action of NSC606985 on cell growth and apoptosis mediated through PKCδ in prostatic cancer cells. International journal of oncology, 2017, Volume: 51, Issue:5 Topics: Acetophenones; Apoptosis; Benzopyrans; Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Humans; Male; Precision Medicine; Prostatic Neoplasms; Protein Kinase C-delta	2017
Characterization and antitumor activity of camptothecin from endophytic fungus African health sciences, 2017, Volume: 17, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Camptotheca; Camptothecin; Cell Line, Tumor; Chlorocebus aethiops; Chromatography, High Pressure Liquid; Endophytes; Fusarium; Humans; Male; Prostatic Neoplasms; Vero Cells	2017
FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-X BMC cancer, 2018, 01-22, Volume: 18, Issue:1 Topics: Animals; Apoptosis; bcl-X Protein; Biomarkers, Tumor; Camptothecin; Cell Death; Cell Line, Tumor; Cell Survival; Cytokines; Humans; Male; Mice; Neoplasm Proteins; Prostate; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays	2018
Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer. Pharmacological reports : PR, 2018, Volume: 70, Issue:3 Topics: Antineoplastic Agents; Cadherins; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chitosan; Claudin-1; Drug Delivery Systems; Humans; Irinotecan; Male; Nanoparticles; Prostatic Neoplasms; RNA, Small Interfering; Snail Family Transcription Factors	2018
Molecular Engineering-Based Aptamer-Drug Conjugates with Accurate Tunability of Drug Ratios for Drug Combination Targeted Cancer Therapy. Angewandte Chemie (International ed. in English), 2019, 08-19, Volume: 58, Issue:34 Topics: Antineoplastic Agents; Aptamers, Nucleotide; Camptothecin; Dasatinib; Drug Carriers; Drug Delivery Systems; Humans; Male; Molecular Targeted Therapy; Paclitaxel; Prostatic Neoplasms; Stilbenes; Tumor Cells, Cultured	2019
Two-stage operation for synchronous triple primary cancer of the esophagus, stomach, and ampulla of Vater: report of a case. Surgery today, 2014, Volume: 44, Issue:5 Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Common Bile Duct Neoplasms; Diagnostic Imaging; Digestive System Surgical Procedures; Esophageal Neoplasms; Fatal Outcome; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Plastic Surgery Procedures; Prostatic Neoplasms; Stomach Neoplasms	2014
Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I. The Biochemical journal, 2013, Jul-01, Volume: 453, Issue:1 Topics: Apoptosis; Camptothecin; Cell Line, Tumor; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Homeodomain Proteins; Humans; Male; Prostatic Neoplasms; Transcription Factors; Tumor Suppressor Proteins	2013
Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure. Molecular cancer, 2013, Oct-08, Volume: 12, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Camptothecin; Cell Line, Tumor; Cell Transformation, Neoplastic; Coculture Techniques; Drug Resistance, Neoplasm; Humans; Inflammation Mediators; Male; Neoplasm Grading; Phenotype; Phosphoproteins; Prostatic Neoplasms; Proteome; Secretory Vesicles; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins	2013
DNA damage response (DDR) via NKX3.1 expression in prostate cells. The Journal of steroid biochemistry and molecular biology, 2014, Volume: 141 Topics: Acid Anhydride Hydrolases; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle; Cell Line, Tumor; Cyclin D1; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Activated Protein Kinase; DNA-Binding Proteins; Doxorubicin; Etoposide; Histones; Homeodomain Proteins; Humans; Hydrogen Peroxide; Irinotecan; Male; Metribolone; Mutagens; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Testosterone Congeners; Transcription Factors	2014
A novel multifunctional poly(amidoamine) dendrimeric delivery system with superior encapsulation capacity for targeted delivery of the chemotherapy drug 10-hydroxycamptothecin. International journal of pharmaceutics, 2014, Apr-25, Volume: 465, Issue:1-2 Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chemistry, Pharmaceutical; Dendrimers; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Endocytosis; Female; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Integrin alphaVbeta3; Kinetics; Male; MCF-7 Cells; Peptides, Cyclic; Polyamines; Prostatic Neoplasms; Solubility; Surface Properties; Technology, Pharmaceutical	2014
Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells. PloS one, 2014, Volume: 9, Issue:2 Topics: Antineoplastic Agents; Base Sequence; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Immediate-Early Proteins; Male; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Topoisomerase Inhibitors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2014
Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia. Molecular pharmacology, 2014, Volume: 85, Issue:6 Topics: Antineoplastic Agents; Base Sequence; Benzimidazoles; Camptothecin; Cell Hypoxia; Cell Line, Tumor; DNA Damage; DNA Primers; DNA, Neoplasm; E2F1 Transcription Factor; Humans; Irinotecan; Male; Polymerase Chain Reaction; Prostatic Neoplasms; Rad51 Recombinase; Tumor Suppressor Protein p53; Up-Regulation	2014
BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs. Cancer research, 2015, Apr-01, Volume: 75, Issue:7 Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Protein Tyrosine Phosphatases, Non-Receptor; Protein-Tyrosine Kinases	2015
Camptothecin suppresses expression of matrix metalloproteinase-9 and vascular endothelial growth factor in DU145 cells through PI3K/Akt-mediated inhibition of NF-κB activity and Nrf2-dependent induction of HO-1 expression. Environmental toxicology and pharmacology, 2015, Volume: 39, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Male; Matrix Metalloproteinase 9; NF-kappa B; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Tetradecanoylphorbol Acetate; Vascular Endothelial Growth Factor A	2015
In Vitro and In Vivo Therapeutic Evaluation of Camptothecin-Encapsulated β-Cyclodextrin Nanosponges in Prostate Cancer. Journal of biomedical nanotechnology, 2016, Volume: 12, Issue:1 Topics: Absorption, Physicochemical; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; beta-Cyclodextrins; Camptothecin; Cell Line, Tumor; Cell Survival; Diffusion; Humans; Male; Mice; Mice, SCID; Nanocapsules; Porosity; Prostatic Neoplasms	2016
Tumor Microenvironment-Responsive Nanoparticle Delivery of Chemotherapy for Enhanced Selective Cellular Uptake and Transportation within Tumor. Biomacromolecules, 2016, 12-12, Volume: 17, Issue:12 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Drug Delivery Systems; Hyaluronic Acid; Irinotecan; Macrophages; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Polyesters; Polyglycolic Acid; Prostatic Neoplasms; Tumor Cells, Cultured; Tumor Microenvironment	2016
A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochemical and biophysical research communications, 2008, Aug-29, Volume: 373, Issue:3 Topics: Androgens; Antineoplastic Agents; Benzamides; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Humans; Male; Naphthols; Prostatic Neoplasms; Sirtuin 1; Sirtuins; Up-Regulation	2008
Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Molecular cancer therapeutics, 2008, Volume: 7, Issue:7 Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cell Line, Tumor; Cell Survival; Ceramides; Drug Therapy, Combination; Green Fluorescent Proteins; Humans; Irinotecan; Lysophospholipids; Male; Mice; Neoplasm Metastasis; para-Aminobenzoates; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; Sphingosine; Treatment Outcome; Xenograft Model Antitumor Assays	2008
Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochemical and biophysical research communications, 2008, Dec-05, Volume: 377, Issue:1 Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; Binding Sites; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Prostatic Neoplasms; Sirtuin 1; Sirtuins; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53	2008
Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression. The Prostate, 2010, Feb-01, Volume: 70, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Taxoids	2010
Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. International journal of clinical oncology, 2009, Volume: 14, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Carcinoma, Small Cell; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Neoplasm Recurrence, Local; Peptide Fragments; Prostatic Neoplasms; Recombinant Proteins; Spinal Puncture; Treatment Outcome	2009
Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth. Biochemical and biophysical research communications, 2010, Apr-02, Volume: 394, Issue:2 Topics: Active Transport, Cell Nucleus; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; HSP90 Heat-Shock Proteins; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Topoisomerase I Inhibitors; Transcription, Genetic	2010
Amphiphilic block co-polyesters bearing pendant cyclic ketal groups as nanocarriers for controlled release of camptothecin. Journal of biomaterials science. Polymer edition, 2011, Volume: 22, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Camptothecin; Caproates; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Drug Carriers; Glass; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; Lactones; Male; Nanoparticles; Particle Size; Polyesters; Polyethylene Glycols; Prostatic Neoplasms; Surface-Active Agents; Transition Temperature	2011
p53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells. The Prostate, 2011, Jan-01, Volume: 71, Issue:1 Topics: Aconitate Hydratase; Camptothecin; Carcinoma; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Mitochondria; Mutation; Prostatic Neoplasms; Response Elements; Thiazoles; Tumor Suppressor Protein p53	2011
Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Ascorbic Acid; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dehydroascorbic Acid; Docetaxel; Drug Synergism; Epirubicin; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine	2011
Use of irinotecan for treatment of small cell carcinoma of the prostate. The Prostate, 2011, May-15, Volume: 71, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Therapy, Combination; Humans; Irinotecan; Male; Mice; Mice, Inbred NOD; Mice, SCID; Prostatic Neoplasms; Subrenal Capsule Assay	2011
Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation. The Journal of pharmacy and pharmacology, 2011, Volume: 63, Issue:6 Topics: Ammonium Sulfate; Animals; Antineoplastic Agents; beta-Cyclodextrins; Camptothecin; Capsules; Female; Half-Life; Irinotecan; Lipids; Liposomes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Polyethylene Glycols; Prostatic Neoplasms; Technology, Pharmaceutical	2011
Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells. Free radical research, 2011, Volume: 45, Issue:9 Topics: Alkanesulfonic Acids; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cisplatin; Gene Expression Regulation, Neoplastic; Humans; Hydrogen Peroxide; Male; Membrane Potential, Mitochondrial; NADPH Oxidases; Prostatic Neoplasms; Reactive Oxygen Species	2011
NKX3.1 contributes to S phase entry and regulates DNA damage response (DDR) in prostate cancer cell lines. Biochemical and biophysical research communications, 2011, Oct-14, Volume: 414, Issue:1 Topics: Androgens; Camptothecin; Cell Line, Tumor; DNA Damage; Histones; Homeodomain Proteins; Humans; Irinotecan; Male; Prostatic Neoplasms; S Phase; Transcription Factors	2011
Time schedule-dependent effect of the CK2 inhibitor TBB on PC-3 human prostate cancer cell viability. Oncology reports, 2012, Volume: 27, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 2; Enzyme Inhibitors; Humans; Male; Prostatic Neoplasms; Protein Serine-Threonine Kinases; TNF-Related Apoptosis-Inducing Ligand; Triazoles	2012
Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. Anticancer research, 2012, Volume: 32, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Drug Synergism; Etoposide; Flow Cytometry; Fluorouracil; Humans; Inhibitor of Apoptosis Proteins; Male; Prostatic Neoplasms; Quercetin; Survivin; Tumor Stem Cell Assay; Tumor Suppressor Protein p53	2012
Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKCδ-independent pathway. Biochemical pharmacology, 2012, Jul-01, Volume: 84, Issue:1 Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzopyrans; Blotting, Western; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; DNA Cleavage; DNA Topoisomerases, Type I; Drug Synergism; Flow Cytometry; Humans; In Situ Nick-End Labeling; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protein Kinase C-delta; RNA, Small Interfering; Topoisomerase I Inhibitors; Transfection	2012
Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2012, Nov-20, Volume: 47, Issue:4 Topics: Androgens; Antineoplastic Agents; beta-Cyclodextrins; Camptothecin; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; DNA Damage; Drug Carriers; Histones; Humans; Male; Nanostructures; Particle Size; Phosphorylation; Prostatic Neoplasms; Solubility; Topoisomerase I Inhibitors	2012
Camptothecins in tumor homing via an RGD sequence mimetic. Bioorganic & medicinal chemistry letters, 2012, Oct-15, Volume: 22, Issue:20 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Integrins; Male; Oligopeptides; Ovarian Neoplasms; Prostatic Neoplasms; Rats	2012
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (London, England), 2013, Volume: 8, Issue:5 Topics: Antigens, Surface; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Delivery Systems; Drug Synergism; Glutamate Carboxypeptidase II; Humans; Irinotecan; Male; Nanoparticles; Polymers; Prostate; Prostatic Neoplasms	2013
Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells. International journal of molecular sciences, 2012, Sep-28, Volume: 13, Issue:10 Topics: Animals; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Coculture Techniques; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Engineering; Humans; Interferon-beta; Irinotecan; Male; Prodrugs; Prostatic Neoplasms; Rabbits; Stem Cells	2012
Green tea polyphenols induce p53-dependent and p53-independent apoptosis in prostate cancer cells through two distinct mechanisms. PloS one, 2012, Volume: 7, Issue:12 Topics: Acetylation; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Gene Knockdown Techniques; Histone Deacetylases; Histones; Humans; Male; Models, Biological; Phosphorylation; Phosphoserine; Polyphenols; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Binding; Proto-Oncogene Proteins c-akt; Receptors, Death Domain; Signal Transduction; Tea; Tumor Suppressor Protein p53	2012
Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells. Cancer biology & therapy, 2013, Volume: 14, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Cetrimonium; Cetrimonium Compounds; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Middle Aged; Prostatic Neoplasms; RNA, Small Interfering; Surface-Active Agents	2013
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. The Prostate, 2003, Feb-15, Volume: 54, Issue:3 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Fluorouracil; Genetic Therapy; Humans; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Nuclear Proteins; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2003
Camptothecin poly[n-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy. Molecular cancer therapeutics, 2003, Volume: 2, Issue:1 Topics: Acrylamides; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Esters; Female; Humans; Lung Neoplasms; Male; Methacrylates; Mice; Mice, Nude; Prostatic Neoplasms; Spectrometry, Fluorescence; Structure-Activity Relationship; Tissue Distribution; Transplantation, Heterologous	2003
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer research, 2003, Mar-01, Volume: 63, Issue:5 Topics: Androstadienes; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Oligonucleotide Array Sequence Analysis; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Wortmannin	2003
Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Blotting, Western; Camptothecin; Carrier Proteins; Cell Division; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; Cyclic AMP-Dependent Protein Kinases; DNA, Complementary; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Enzyme Inhibitors; Humans; Male; Oligonucleotides; Oligonucleotides, Antisense; Oligoribonucleotides, Antisense; Prostatic Neoplasms; Protein Isoforms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Up-Regulation	2003
Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models. Biochemical pharmacology, 2003, Apr-15, Volume: 65, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; DNA Damage; DNA, Neoplasm; Humans; Male; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured	2003
The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:3 Topics: Animals; Breast Neoplasms; Camptothecin; Female; Humans; Hydrogen-Ion Concentration; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2003
Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer research, 2003, Aug-01, Volume: 63, Issue:15 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Camptothecin; Caspase 3; Caspase 7; Caspases; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Membrane Glycoproteins; Mice; Mice, Nude; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays	2003
Indolizino[1,2-b]quinolines derived from A-D rings of camptothecin: synthesis and DNA interaction. Journal of enzyme inhibition and medicinal chemistry, 2003, Volume: 18, Issue:2 Topics: Animals; Antineoplastic Agents; Camptothecin; Cattle; Cell Survival; DNA; DNA Footprinting; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Male; Prostatic Neoplasms; Structure-Activity Relationship; Thymus Gland; Tumor Cells, Cultured	2003
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics. British journal of cancer, 2003, Nov-03, Volume: 89, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured	2003
IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. Journal of immunology (Baltimore, Md. : 1950), 2004, May-01, Volume: 172, Issue:9 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; Camptothecin; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cell Survival; Etoposide; fas Receptor; Female; Humans; Interleukin-4; Intracellular Signaling Peptides and Proteins; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Up-Regulation	2004
Reduction of 9-nitrocamptothecin-triggered apoptosis in DU-145 human prostate cancer cells by ectopic expression of 14-3-3zeta. International journal of oncology, 2004, Volume: 25, Issue:2 Topics: 14-3-3 Proteins; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspases; Cloning, Molecular; Drug Resistance, Neoplasm; Gene Expression; Humans; Male; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Transfection; Tumor Cells, Cultured	2004
BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo. Cancer research, 2004, Jul-15, Volume: 64, Issue:14 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Superhelical; Drug Screening Assays, Antitumor; Drug Stability; Enzyme Inhibitors; HL-60 Cells; Humans; K562 Cells; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays	2004
HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. Cancer research, 2004, Dec-15, Volume: 64, Issue:24 Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 4; Membrane Glycoproteins; Mitogen-Activated Protein Kinase Kinases; Oligoribonucleotides; Prostatic Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Necrosis Factor-alpha	2004
[Molecular biology methods in cancer medicine: options beyond steel instrument, ray and chemotherapy]. MMW Fortschritte der Medizin, 2004, Nov-18, Volume: 146, Issue:47 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Immunotherapy; Irinotecan; Male; Mutation; Neoplasms; Prostatic Neoplasms; Research; Simplexvirus; Trastuzumab; Vascular Endothelial Growth Factor A	2004
Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-15, Volume: 11, Issue:6 Topics: Androgens; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspases; Drug Therapy, Combination; Enzyme Activation; Etoposide; Humans; JNK Mitogen-Activated Protein Kinases; Male; Organoselenium Compounds; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Tumor Cells, Cultured	2005
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Methods in molecular medicine, 2005, Volume: 111 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Cytosine; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Fluorouracil; Green Fluorescent Proteins; Humans; Immunotherapy; Interferons; Liposomes; Liver; Liver Neoplasms; Luminescent Proteins; Lung Neoplasms; Male; Metalloproteases; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Red Fluorescent Protein	2005
Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer research, 2005, Dec-15, Volume: 65, Issue:24 Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Ceramides; Disease Models, Animal; Docetaxel; Flow Cytometry; Green Fluorescent Proteins; Humans; Lysophospholipids; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; RNA Interference; Sphingosine; Taxoids; Tumor Cells, Cultured	2005
Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells. Biochemical pharmacology, 2006, Mar-14, Volume: 71, Issue:6 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Caspase 8; Caspases; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; Gene Silencing; Genetic Vectors; Humans; Male; Membrane Glycoproteins; Prostatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Transfection; Tumor Necrosis Factor-alpha; Up-Regulation	2006
Expression of drug pathway proteins is independent of tumour type. The Journal of pathology, 2006, Volume: 209, Issue:2 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Lymphoma; Male; Melanoma; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Tissue Array Analysis	2006
High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochemical and biophysical research communications, 2006, Apr-21, Volume: 342, Issue:4 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Male; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; Receptors, Lysosphingolipid; Up-Regulation	2006
A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer letters, 2007, Feb-08, Volume: 246, Issue:1-2 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Adhesion; Cell Line, Tumor; Cell Movement; Female; Humans; Integrin alphaVbeta3; Integrins; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, Vitronectin; Signal Transduction; Somatostatin	2007
Potent antitumor activity of 10-methoxy-9-nitrocamptothecin. Molecular cancer therapeutics, 2006, Volume: 5, Issue:4 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Survival; Humans; Lung Neoplasms; Male; Mice; Prostatic Neoplasms; Transplantation, Heterologous	2006
Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology, 2006, Volume: 147, Issue:10 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Immunoprecipitation; Male; Phenotype; Prostatic Neoplasms	2006
Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells. Experimental oncology, 2006, Volume: 28, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Clusterin; Drug Resistance, Neoplasm; Humans; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Neoplasm Proteins; Prostatic Neoplasms; Survivin; X-Linked Inhibitor of Apoptosis Protein	2006
A comparative study of protein profiling by proteomic analysis in camptothecin-resistant PC3 and camptothecin-sensitive LNCaP human prostate cancer cells. Urologia internationalis, 2006, Volume: 77, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Electrophoresis, Polyacrylamide Gel; Humans; Male; Mass Spectrometry; Neoplasm Proteins; Prostatic Neoplasms; Proteome; Tumor Cells, Cultured	2006
S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. Molecular cancer therapeutics, 2007, Volume: 6, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA-Binding Proteins; Down-Regulation; Drug Synergism; Enzyme Activation; Humans; Irinotecan; Ligands; Male; Mice; Prostatic Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; Receptors, TNF-Related Apoptosis-Inducing Ligand; S Phase; TNF-Related Apoptosis-Inducing Ligand; Transplantation, Heterologous; Tumor Suppressor Proteins	2007
[Neuroendocrine carcinoma of the prostate effectively treated by cisplatin and irinotecan--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Prostate-Specific Antigen; Prostatic Neoplasms	2007
Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. International journal of cancer, 2008, Apr-01, Volume: 122, Issue:7 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Cyclin A; Cyclin A1; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Interleukin-6; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Phosphatidylinositol 3-Kinases; Plasmids; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Transfection; Transplantation, Heterologous; Up-Regulation	2008
NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells. Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cytochromes c; DNA Fragmentation; Flow Cytometry; Humans; Male; Prostatic Neoplasms	2009
Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968. European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:9 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Caspase 3; DNA Damage; Drug Evaluation; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured	2008
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer research, 1995, Sep-01, Volume: 55, Issue:17 Topics: Apoptosis; Breast Neoplasms; Camptothecin; Cell Division; Dimethyl Sulfoxide; Drug Screening Assays, Antitumor; G1 Phase; Humans; Leukemia, Promyelocytic, Acute; Male; Naphthoquinones; Prostatic Neoplasms; Resting Phase, Cell Cycle; Time Factors; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay	1995
In vitro sequence-dependent synergistic effect of suramin and camptothecin. European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:11 Topics: Camptothecin; Cell Cycle; Cell Division; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms; Suramin; Tumor Cells, Cultured	1994
Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro. The Prostate, 1993, Volume: 23, Issue:1 Topics: Amsacrine; Camptothecin; Cell Survival; Chemical Precipitation; DNA Damage; Dose-Response Relationship, Drug; Drug Interactions; Etoposide; Humans; Male; Prostatic Neoplasms; Suramin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured	1993
Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine. Urology, 1996, Volume: 48, Issue:3 Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Estramustine; Humans; Male; Prostatic Neoplasms; Rats	1996
Induction of apoptosis in malignant and camptothecin-resistant human cells. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Androgens; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Cycle; Cell Cycle Proteins; DNA Topoisomerases, Type I; Drug Interactions; Drug Resistance; Enzyme Inhibitors; Etoposide; Humans; Male; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Suramin; Tumor Cells, Cultured	1996
Antitumor effect of CPT-11, a new derivative of camptothecin, against human prostate cancer (PC-3) in vitro and prostate rat tumor (AT-3) in vivo. Methods and findings in experimental and clinical pharmacology, 1996, Volume: 18, Issue:10 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Male; Neoplasm Transplantation; Prostatic Neoplasms; Rats; Tumor Cells, Cultured	1996
Establishment of human prostate tumor xenografts in nude mice and response to 9-nitrocamptothecin in vivo and in vitro does not correlate with the expression of various apoptosis-regulating proteins. Journal of experimental therapeutics & oncology, 1996, Volume: 1, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Flow Cytometry; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prostatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured	1996
Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer. Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:8 Suppl 6 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Male; Outcome Assessment, Health Care; Palliative Care; Prostatic Neoplasms; Quality of Life; Research Design	1998
9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:2 Topics: Animals; Antineoplastic Agents; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lactones; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prostatic Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured	1997
Indolocarbazole poisons of human topoisomerase I: regioisomeric analogues of ED-110. Bioorganic & medicinal chemistry letters, 1999, Jan-18, Volume: 9, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Carbazoles; Female; Glucosides; HT29 Cells; Humans; Inhibitory Concentration 50; Male; Ovarian Neoplasms; Prostatic Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured	1999
Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis. British journal of cancer, 1999, Volume: 80, Issue:3-4 Topics: Androgens; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspases; Cytotoxicity, Immunologic; Enzyme Activation; Fas Ligand Protein; fas Receptor; Humans; Immunoglobulin M; Male; Membrane Glycoproteins; Mitochondria; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Reactive Oxygen Species; Tumor Cells, Cultured	1999
Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer research, 1999, Nov-15, Volume: 59, Issue:22 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carboxylic Acids; Ceramides; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fumonisins; Humans; Male; Molecular Weight; Neoplasm Proteins; Oxidoreductases; Prostatic Neoplasms; Proteins; Tumor Cells, Cultured	1999
Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis. British journal of cancer, 2000, Volume: 82, Issue:11 Topics: Androgens; Anisomycin; Antibodies; Antineoplastic Agents, Phytogenic; Apoptosis; Base Sequence; Camptothecin; DNA Primers; Enzyme Activation; fas Receptor; Humans; Male; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Signal Transduction; Tumor Cells, Cultured	2000
Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations. Cancer research, 2000, Dec-01, Volume: 60, Issue:23 Topics: Animals; Antineoplastic Agents; Camptothecin; Cricetinae; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Enzyme Stability; Humans; Inhibitory Concentration 50; Leukemia P388; Male; Mice; Point Mutation; Prostatic Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured	2000
The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Enzyme Inhibitors; Growth Inhibitors; Humans; Irinotecan; Male; Mice; Prostatic Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2000
The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison. Anti-cancer drugs, 2001, Volume: 12, Issue:1 Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Cell Division; Cell-Free System; DNA; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Drug Stability; Enzyme Inhibitors; Female; Humans; Male; Mice; Mice, Nude; Osteonectin; Prostatic Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2001
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer research, 2001, Mar-01, Volume: 61, Issue:5 Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Catalysis; DNA Topoisomerases, Type I; DNA, Viral; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Male; Molecular Sequence Data; Mutation; Prostatic Neoplasms; Recombinant Proteins; Sequence Homology, Amino Acid; Simian virus 40; Topoisomerase I Inhibitors; Tumor Cells, Cultured	2001
beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. Experimental cell research, 2001, Jul-01, Volume: 267, Issue:1 Topics: Antibiotics, Antineoplastic; Apoptosis; Camptothecin; Caspases; Dicumarol; Enzyme Inhibitors; Humans; Male; NAD(P)H Dehydrogenase (Quinone); Naphthoquinones; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Transformation, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2001
Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short). Cancer research, 2001, Oct-01, Volume: 61, Issue:19 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 7; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Down-Regulation; Enzyme Activation; Enzyme Precursors; Fas Ligand Protein; fas Receptor; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Glycoproteins; Prostatic Neoplasms; Transfection; Tumor Cells, Cultured	2001
[Globalization of anti-cancer therapies]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms	2002
Ceramide accumulation is independent of camptothecin-induced apoptosis in prostate cancer LNCaP cells. Biochemical and biophysical research communications, 2002, Jun-07, Volume: 294, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Camptothecin; Carboxylic Acids; Caspases; Ceramides; DNA Fragmentation; Enzyme Activation; Enzyme Inhibitors; Fumonisins; Humans; Male; Oxidoreductases; Prostatic Neoplasms; Sphingomyelin Phosphodiesterase; Sphingomyelins; Tumor Cells, Cultured	2002
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. International journal of oncology, 2002, Volume: 21, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome	2002
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, phar International journal of oncology, 2002, Volume: 21, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome	2002